International clinical experience with a new low-dose, monophasic oral contraceptive containing levonorgestrel 100 μg and ethinyl estradiol 20 μg

Clinical Therapeutics

Volumn 21, Issue 1, 1999, Pages 118-127

  Boerrigter, Peter J ^a   Ellman, Herman ^a   Dolker, Michael ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Ethinyl estradiol; Levonorgestrel; Low dose; Oral contraceptives

Indexed keywords

ETHINYLESTRADIOL; LEVONORGESTREL; LOW DOSE ORAL CONTRACEPTIVE;

ARTICLE; BIRTH CONTROL; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESTROGEN THERAPY; FEMALE; GYNECOLOGICAL EXAMINATION; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; OVULATION INHIBITION; STROKE; VEIN THROMBOSIS;

EID: 0033009406     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)88272-7     Document Type: Article

References (12)

1. 1. Hedon B. The evolution of oral contraceptives: Maximizing efficacy, minimizing risks. Acta Obstet Gynecol Scand Suppl. 1990;152:7-12.
2. 2. Rosenberg L, Palmer JR, Sands MI, et al. Modern oral contraceptives and cardiovascular disease. Am J Obstet Gynecol. 1997;177:707-715.
3. 3. Spona J, Feichtinger W, Kindermann CH, et al. Inhibition of ovulation by an oral contraceptive containing 100 μg levonorgestrel in combination with 20 μg ethinylestradiol. Contraception. 1996;54: 299-304.
4. 4. Bannemerschult R, Hanker JP, Wünsch C, et al. A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel over six treatment cycles. Contraception. 1997;56:285-290.
5. 5. Tietze C, Lewit S. Statistical evaluation of contraceptive methods. Clin Obstet Gynecol. 1974;17:121-138.
6. 6. Sartoretto JN, Ortega-Recio JC. Clinical evaluation of a low dosage estrogen-progesterone association (100 μg of d-norgestrel and 20 μg of ethinyl estradiol). Rev Bras Clin Terap. 1974;3: 399-404. In Portuguese.
7. 7. Archer DF, Maheux R, DelConte A, O'Brien FB, and the North American Levonorgestrel Study Group (NALSG). A new low-dose monophasic combination oral contraceptive (Alesse™) with levonorgestrel 100 μg and ethinyl estradiol 20 μg. Contraception. 1997;55:139-144.
8. 8. Endikrat J, Müller U, Düsterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 μg ethinylestradiol/75 μg gestodene and 30 μg ethinylestradiol/75 μg gestodene, with respect to efficacy, cycle control, and tolerance. Contraception. 1997;55:131-137.
9. 9. Kirkman RJE, Pedersen JH, Fioretti P, Roberts HE. Clinical comparison of two low-dose oral contraceptives, Minulet® and Mercilon®, in women over 30 years of age. Contraception. 1994;49:33-46.
10. 10. The Mircette® Study Group. An open-label, multicenter, noncomparative safety and efficacy study of Mircette®, a low-dose estrogen-progestin oral contraceptive. Am J Obstet Gynecol. 1998;179:S2-S8.
11. 11. Rosenberg MJ, Long SC. Oral contraceptives and cycle control: A critical review of the literature. Adv Contracept. 1992; 8(Suppl 1):35-45.
12. 12. Gardner MJ, Altman DG, eds. Statistics with Confidence. Confidence Intervals and Statistical Guidelines. London: British Medical Journal; 1989:285-299.